CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 3 pages
National Center for Immunization & Respiratory Diseases Influenza B/Yamagata Update Lisa Grohskopf, MD, MPH Advisory Committee on Immunization Practices February 28, 2024 •Quadrivalent influenza vaccines introduced in 2013 -14 to provide broader coverage of influenza B viruses. –Quadrivalents contain one influenza B virus from each lineage (Victoria and Yamagata). –Transition from trivalents to quadrivalents complete by the 2021 -22 influenza season. •No confirmed influenza B/Yamagata viruses…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 2 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 41 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 12 pages
Pneumococcal Vaccines Work Group Considerations and Next Steps Miwako Kobayashi, MD, MPH Pneumococcal Vaccines Work Group Advisory Committee on Immunization Practices February 22, 2023 Proposed Policy Questions Should PCV20 be recommended as an option for pneumococcal conjugate vaccination according to currently recommended dosing and schedules, for U.S. children aged <2 years? Should PCV20 without PPSV23 be recommended as…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 8 pages
National Center for Immunization & Respiratory Diseases ACIP Meningococcal Vaccines Work Group Introduction Katherine Poehling, MD, MPH Work Group Chair February 23, 2023 Meningococcal Vaccines Work Group ACIP Members – Kat herine Poehling (Chair) – Lynn Bahta – Jam ie Loehr Ex Officio Members – Mar garet Bash (FDA) – Mark Connelly (FDA) – Fra ncisco Leyva (NIH) CDC Lead – Sam…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 17 pages
National Center for Immunization & Respiratory Diseases Epidemiology of Meningococcal Disease in the United States Amy Rubis, MPH Advisory Committee on Immunization Practices Meeting February 23, 2023 Agenda Overall epidemiology of meningococcal disease in the United States Recent notable epidemiology – C iprofloxacin- and penicillin-resistant serogroup Y meningococcal disease cases – Outbreaks 2 Meningococcal Disease Surveillance …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 26 pages
1 Pfizer ConfidentialMenABCWY Meningococcal Vaccine Jason D. Maguire, MD, MPH Clinical Lead, Phase 3 Program Pfizer Vaccines Clinical R&D 2 Pfizer Confidential For Internal and Restricted Pfizer Use Only –Not for Distribution. Privileged and Confidential.MenABCWY vaccine composition Confidential•MenABCWY vaccine is composed of drug substance from: –Trumenba®(MenB-fHbp): licensed in the US for the prevention of invasive disease caused by Neisseria meningitidis group B in individuals 10…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 15 pages
National Center for Immunization & Respiratory Diseases Work Group Interpretation of Pfizer’s MenABCWY Vaccine Clinical Trials Data Sam Crowe, PhD, MPH Meningococcal Vaccines Work Group Lead February 23, 2023 Policy Questions for Each Pentavalent Vaccine Should the pentavalent vaccine be included as an option for MenACWY/MenB vaccination in people currently recommended to receive both…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 2 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory DiseasesCenters for Disease Control and Prevention National Center for Immunization and Respiratory DiseasesCenters for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases ACIP Polio Vaccination Work Group Oliver Brooks, MD, FAAP ACIP Meeting February 23, 2023 …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 29 pages
CCCCenen enentt ttererer ers sss f fffo ooorrr r DiDi DiDiss sseaea eaeassssee e e CCCCoooonnnnttt trrr roooollll aaaannnndddd PP PPrr rreeeevvvvenenenenttttiii iooo onnnn NNN Naaaatttti iiio ooonn nnaaaallll CC CCeeeennnnttt tee eerrrr ffffoooorrrr II IImmmmmm mmuuuunnnni iiiz zzza aaat ttti iiio ooonn nn aaaann nndddd RR RReeeespsp spspiii ir rrra aaattttoo oorrrryyyy DDDDiiiisese sesea aaase sesesess ss Adult Polio Vaccination Sarah Kidd, MD, MPH ACIP…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 5 pages
1 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group Sarah S. Long, MD Chair,…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 40 pages
Economic Analysis of Nirsevimab in Pediatric Populations David W. Hutton, PhD, MS Associate Professor, Health Management and Policy, School of Public Health Associate Professor of Global Public Health, School of Public Health Associate Professor, Industrial and Operations Engineering, College of Engineering University of MichiganACIP General Meeting February 23, 2023 Research Team University of Michigan •David Hutton, PhD •Lisa Prosser, PhD •Angela Rose, MPH •Kerra Me rcon, MSCDC •Jefferson…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 23 pages
Economics of Preventing Respiratory Syncytial Virus Lower Respiratory Tract Infections (RSV- LRTI) among US Infants with Nirsevimab A SUMMARY REPORT COMPARING MODELS FROM: Sanofi AND University of Michigan and CDC Ismael R. Ortega -Sanchez, PhD NCIRD/CDC ACIP Meeting, February 23, 2023 46Disclaimer : The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. National Center for…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 92 pages
Centers for Disease Control and Prevention Evidence to Recommendations Framework: Nirsevimab Jefferson Jones MD MPH FAAP , CDR USPHS ACIP General MeetingFebruary 23, 2023 Evidence to Recommendations Framework 71Nirsevimab is a form of passive immunization Active immunity results from infection or vaccination, which triggers animmune response Passive immunity is when a person receives antibodies from an external source –From mother to baby through transplacental or breastmilk transfer…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 16 pages
Centers for Disease Control and Prevention Draft Interim Clinical Considerations: Nirsevimab Jefferson Jones MD MPH FAAP , CDR USPHS ACIP General MeetingFebruary 23, 2023 162Goals of recommendations Provide simple, uniform recommendations that apply to most U.S. health care providers Provide flexibility for specific situations 163Policy Question Should one dose of nirsevimab be recommended a) at birth for all infants born during October to March and b) when entering first RSV season and…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 31 pages
MedicalSafety and Efficacy of Bivalent RSV Prefusion F Vaccine in Vaccinated Mothers and their Infants Iona Munjal, MD Senior Director, Vaccine Research and Development 178Worldwide Research, Development and Medical Vaccine Research and DevelopmentBivalent RSV Prefusion F Vaccine Proposed Indication: Prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by respiratory syncytial virus (RSV)DOSE LEVEL•120 µg without an adjuvant •Dose contains 60…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 6 pages
208 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Work Group considerations regarding maternal RSV vaccine Katherine Fleming -Dutra, MD…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 8 pages
Centers for Disease Control and Prevention Adult Respiratory Syncytial Virus (RSV) Session Camille Kotton, MD Chair, Adult RSV Work Group Advisory Committee on Immunization Practices (ACIP) February 23, 2023 2Adult RSV Work Group Membership ACIP Voting Members Camille Kotton (Chair) Keipp Talbot Sarah Long Ex Officio Members Rachel Zhang (FDA) Judy Beeler (FDA) Nicholas Geagan (FDA) Nadine Peart (FDA)Sonnie Kim (NIH/NIAID) Jeffrey Kelman (CMS) Valerie Marshal (OIDP)CDC Lead Michael Melgar…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 37 pages
Economic Analysis of RSV Vaccination in Older Adults David W. Hutton, PhD, MS Associate Professor, Health Management and Policy, School of Public Health Associate Professor of Global Public Health, School of Public Health Associate Professor, Industrial and Operations Engineering, College of Engineering University of Michigan Research Team University of Michigan •David Hutton, PhD •Lisa Prosser, PhD •Angela Rose, MPH •Kerra Me rcon, MSCDC •Michael Me lgar, MD •Mila Prill , MSPH •Jamison…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 24 pages
Economics of Vaccinating U.S. Adults ≥60 years-old against Respiratory Syncytial Virus A SUMMARY REPORT COMPARING MODELS FROM: GSK,Pfizer AND University of Michigan -CDC Ismael R. Ortega -Sanchez, PhD NCIRD/CDC ACIP Meeting, February 23, 2023 1Disclaimer : The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. National Center for Immunization & Respiratory Diseases Conflict of…